151 related articles for article (PubMed ID: 37424146)
1. The serum level of plasmin-alpha2 plasmin inhibitor complex (PIC) is useful for differentiating cardiac light chain amyloidosis from transthyretin amyloidosis.
Shimazaki C; Matsui-Maegawa S; Kimoto-Matsumura Y; Ota-Kuwabara S; Ide D; Fuchida SI; Hatsuse M
Br J Haematol; 2023 Sep; 202(6):1209-1212. PubMed ID: 37424146
[No Abstract] [Full Text] [Related]
2. Elevation of Plasmin-α2-plasmin Inhibitor Complex Predicts the Diagnosis of Systemic AL Amyloidosis in Patients with Monoclonal Protein.
Ishiguro K; Hayashi T; Yokoyama Y; Aoki Y; Onodera K; Ikeda H; Ishida T; Nakase H
Intern Med; 2018 Mar; 57(6):783-788. PubMed ID: 29021469
[TBL] [Abstract][Full Text] [Related]
3. Elevation of Plasmin-α2-plasmin Inhibitor Complexes in Patients with AL Amyloidosis.
Miyazaki K; Suzuki K
Intern Med; 2018 Mar; 57(6):775-776. PubMed ID: 29321425
[No Abstract] [Full Text] [Related]
4. Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis.
Slamova I; Adib R; Ellmerich S; Golos MR; Gilbertson JA; Botcher N; Canetti D; Taylor GW; Rendell N; Tennent GA; Verona G; Porcari R; Mangione PP; Gillmore JD; Pepys MB; Bellotti V; Hawkins PN; Al-Shawi R; Simons JP
Nat Commun; 2021 Dec; 12(1):7112. PubMed ID: 34876572
[TBL] [Abstract][Full Text] [Related]
5. Transthyretin Cardiac Amyloidosis Disguised as Light Chain Amyloidosis or Multiple Myeloma?
Stein AP; Matthia EL; Petty SA; Stewart B; Vilaro JR; Al-Ani MAZ; Ahmed MM; Aranda JM; Hiemenz JW; Parker AM
Am J Cardiol; 2024 Jan; 210():85-92. PubMed ID: 37852567
[TBL] [Abstract][Full Text] [Related]
6. Extracellular Volume Detects Amyloidotic Cardiomyopathy and Correlates With Neurological Impairment in Transthyretin-familial Amyloidosis.
Gallego-Delgado M; González-López E; Muñoz-Beamud F; Buades J; Galán L; Muñoz-Blanco JL; Sánchez-González J; Ibáñez B; Mirelis JG; García-Pavía P
Rev Esp Cardiol (Engl Ed); 2016 Oct; 69(10):923-930. PubMed ID: 27291669
[TBL] [Abstract][Full Text] [Related]
7. Days alive and outside of hospital from diagnosis of transthyretin vs. light chain cardiac amyloidosis.
Rubin J; Teruya S; Helmke S; De Los Santos J; Alvarez J; Maurer MS
Amyloid; 2019; 26(sup1):4-5. PubMed ID: 31343342
[No Abstract] [Full Text] [Related]
8. [Diagnosis and treatment of cardiac transthyretin amyloidosis. Innovative therapy with tafamidis.].
Legrand D; Nyssen A; Jackers L; Brogneaux C; Pirotte I; Grayet D; Lacremans D; Magnée M
Rev Med Liege; 2022 Jan; 77(1):63-68. PubMed ID: 35029343
[TBL] [Abstract][Full Text] [Related]
9. Cardiac amyloidosis: updates in diagnosis and management.
Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
[TBL] [Abstract][Full Text] [Related]
10. Reply: could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac amyloidosis?
Siontis GC; Windecker S
J Am Coll Cardiol; 2015 Jan; 65(3):313. PubMed ID: 25614435
[No Abstract] [Full Text] [Related]
11. Reply: could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac amyloidosis?
Kim WK; Rolf A; Möllmann H
J Am Coll Cardiol; 2015 Jan; 65(3):312-3. PubMed ID: 25614434
[No Abstract] [Full Text] [Related]
12. Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis.
Gertz MA; Benson MD; Dyck PJ; Grogan M; Coelho T; Cruz M; Berk JL; Plante-Bordeneuve V; Schmidt HHJ; Merlini G
J Am Coll Cardiol; 2015 Dec; 66(21):2451-2466. PubMed ID: 26610878
[TBL] [Abstract][Full Text] [Related]
13. Could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac amyloidosis?
Castaño A; Bokhari S; Maurer MS
J Am Coll Cardiol; 2015 Jan; 65(3):311-2. PubMed ID: 25614433
[No Abstract] [Full Text] [Related]
14. Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis.
Halushka MK; Eng G; Collins AB; Judge DP; Semigran MJ; Stone JR
J Cardiovasc Transl Res; 2015 Jun; 8(4):264-8. PubMed ID: 25925232
[TBL] [Abstract][Full Text] [Related]
15. Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis.
Papoutsidakis N; Miller EJ; Rodonski A; Jacoby D
J Card Fail; 2018 Feb; 24(2):131-133. PubMed ID: 29305186
[No Abstract] [Full Text] [Related]
16. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M
Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171
[TBL] [Abstract][Full Text] [Related]
17. A representative case of hereditary transthyretin amyloidosis complicated by intramyocardial hemorrhage.
Yagi H; Amiya E; Shintani Y; Nitta D; Numakura S; Hosoya Y; Watanabe M; Fukayama M; Komuro I
Amyloid; 2015 Mar; 22(1):70-2. PubMed ID: 25427692
[No Abstract] [Full Text] [Related]
18. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
Rubin J; Maurer MS
Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive detection and differentiation of cardiac amyloidosis using
Takasone K; Katoh N; Takahashi Y; Abe R; Ezawa N; Yoshinaga T; Yanagisawa S; Yazaki M; Oguchi K; Koyama J; Sekijima Y
Amyloid; 2020 Dec; 27(4):266-274. PubMed ID: 32722948
[TBL] [Abstract][Full Text] [Related]
20. Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis.
Law S; Fontana M; Gillmore JD
Cardiol Clin; 2021 Aug; 39(3):389-402. PubMed ID: 34247752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
